Correlations between TORCH infections and antiphospholipid antibodies in spontaneous abortion

2020 ◽  
Vol 19 (4) ◽  
pp. 92-98
Author(s):  
E.N. Kravchenko ◽  
◽  
L.V. Kuklina ◽  
G.V. Krivchik ◽  
O.Yu. Tsygankova ◽  
...  
Keyword(s):  
Spontaneous Abortion ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Clinical Symptoms ◽  
Annexin V ◽  
Reciprocal Relation ◽  
Strong Positive Correlation ◽  
Positive Correlation ◽  
Torch Infection ◽  
Torch Infections

Objective. To study correlations between TORCH infections and antiphospholipid antibodies in spontaneous abortion. Patients and methods. We analysed 137 medical records of women with histories of abortion, who were divided into two groups according to the presence/absence of plasmapheresis in their treatment regimens at the stage of pregravid preparation with subsequent ranking to two subgroups according to the presence/absence of an active TORCH infection. Results. A moderate positive correlation was found between the levels of TORCH infection markers and IgМ against cardiolipin, IgМ against annexin V, IgМ against phospholipids. The maximal values of a strong positive correlation was noted in the pairs «TORCH – anticardiolipin IgG» as one of the most specific markers of antiphospholipid syndrome (APS) and «TORCH – antiphospholipid IgG» as the less specific antibodies, whose concentrations significantly increase in case of a TORCH infection, irrespective of the presence of APS. The presence of antibodies against a TORCH infection and correlations between them have shown a reciprocal relation between the markers of a TORCH infection and anticardiolipin IgG, anti-b2-glycoprotein-1 IgG, and TORCH – antiphospholipid IgG. Conclusion. TORCH infections are associated with higher titers of antiphospholipid antibodies, which in certain cases might lead to the appearance of the clinical symptoms of antiphospholipid syndrome. Key words: antiphospholipid antibodies, antiphospholipid syndrome, miscarriage, plasmapheresis, TORCH infection

Features of the medical history and pregnancy outcomes in women with antiphospholipid syndrome depending on correction methods

2020 ◽  
Vol 69 (2) ◽  
pp. 23-32
Author(s):  
Elena N. Kravchenko ◽  
Anastasia A. Goncharova ◽  
Larisa V. Kuklina
Keyword(s):  
Cohort Study ◽  
Medical History ◽  
Antiphospholipid Syndrome ◽  
Pregnancy Outcomes ◽  
Antiphospholipid Antibodies ◽  
Optimal Choice ◽  
Not Given ◽  
Group I ◽  
History Of ◽  
Torch Infection

Hypothesis/aims of study. The aim of this study was to evaluate the features of the medical history and pregnancy outcomes in women with miscarriage and antiphospholipid syndrome depending on the methods of its correction. Study design, materials and methods. A prospective cohort study was conducted, in which a total of 137 pregnant women with a history of abortion and antiphospholipid syndrome were examined. The women were divided into two groups according to the principle of the presence or absence of plasmapheresis procedures in the scheme of miscarriage therapy at the pregravid stage. Group I (main) consisted of individuals (n = 73), who were treated with the inclusion of plasmapheresis at the pregravid stage; group II (comparison) included women (n = 64), who were not given efferent therapy. Results. Antiphospholipid syndrome was more common in patients with a complicated obstetric and gynecological history. As a result of persistent infection, chronic endometritis and salpingo-ooparitis were more often observed in patients with TORCH infection. The titer of antiphospholipid antibodies, regardless of the presence or absence of TORCH infection, decreased after plasmapheresis, such positive dynamics being observed only in patients with a history of gestational losses of less than four. Conclusion. The level of reduction of antiphospholipid antibodies in relation to the initial values was 6095%, which indicates the optimal choice of the characteristics of plasmapheresis therapy and its duration.

scholarly journals Microangiopathic antiphospholipid syndrome (MAPS) in the course of undifferentiated connective tissue disease

2014 ◽  
Vol 83 (1) ◽  
pp. 81-83
Author(s):  
Bożena Targońska-Stępniak ◽  
Ewa Wielosz ◽  
Maria Majdan
Keyword(s):  
Renal Failure ◽  
Connective Tissue ◽  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Renal Damage ◽  
Kidney Biopsy ◽  
Clinical Symptoms ◽  
Renal Involvement ◽  
Undifferentiated Connective Tissue Disease ◽  
Anticoagulant Treatment

Introduction. The microangiopathic antiphospholipid syndrome (MAPS) is a subset of APS comprising those patients presenting with thrombotic microangiopathy and demonstrable antiphospholipid antibodies. Renal involvement occurs frequently in the course of MAPS with clinical symptoms of acute renal failure, hypertension, proteinuria and erythrocyturia. Case report. The report presents the patient with MAPS confirmed by kidney biopsy in the course of undifferentiated connective tissue disease.Conclusion. The authors emphasize the importance of effective anticoagulant treatment in order to inhibit thrombosis and renal damage in the course of MAPS.

Annexin V antibodies in multiple sclerosis and SLE/APS

Open Medicine ◽  
2013 ◽  
Vol 8 (2) ◽  
pp. 225-228
Author(s):  
Marta Baleva ◽  
Detelina Stoilova ◽  
Petko Shotekov ◽  
Krasimir Nikolov
Keyword(s):  
Multiple Sclerosis ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Annexin V ◽  
Serum Levels ◽  
Organ Damage ◽  
Systemic Lupus ◽  
Pathogenic Role ◽  
Glycoprotein I

AbstractMultiple sclerosis (MS) is an autoimmune disease with unclear etiopathogenesis. Some MS patients have anticardiolipin (ACL), anti-beta-2-glycoprotein-I (B2GPI) and anti-annexin V (AnV) antibodies. These antibodies can also be found in systemic lupus erythematosus with antiphospholipid syndrome (SLE/APS). The aim of our study was to compare the levels of ACL, B2GPI and AnV antibodies in MS and SLE/APS. Materials and methods: We investigated serum levels of IgG and IgM ACL, B2GPI and AnV in 21 MS patients, 30 SLE/APS patients and 30 controls using ELISA. Results: Mean levels of IgM and IgG ACL and B2GPI in MS were comparable with controls and lower than SLE/APS (p<0.05). Mean levels of IgM AnV in MS were higher compared to SLE/APS and controls (p<0.05); mean levels of IgG AnV in MS were higher than normal but similar to SLE/APS (p>0.05). Discussion: The results show that MS with negative “classic” autoantibodies (ACL and B2GPI) and without clinical data for antiphospholipid syndrome may have other positive antiphospholipid antibodies, such as AnV. Larger studies are needed to clarify whether AnV are epiphenomenon of the vascular and organ damage or they play a pathogenic role in the development of MS.

Non β2-Glycoprotein I Cofactors for Antiphospholipid Antibodies

Lupus ◽  
1996 ◽  
Vol 5 (5) ◽  
pp. 388-392 ◽  
Author(s):  
M Galli
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Protein C ◽  
Activated Protein C ◽  
Clinical Manifestations ◽  
Annexin V ◽  
Protein S ◽  
Thromboembolic Events ◽  
Glycoprotein I ◽  
Recurrent Abortions

The Antiphospholipid Syndrome is defined by the association between peculiar clinical manifestations, namely arterial and/or venous thrombosis, recurrent abortions and thrombocytopenia, and the antiphospholipid antibodies. These antibodies are directed to plasma proteins bound to anionic phospholipids or other anionic surfaces: so far, β2-glycoprotein I is the best known and characterized antiphospholipid ‘cofactor’ ( this issue is specifically treated in other parts of this journal). In recent years, such a role has been reported also for prothrombin, activated Protein C, Protein S, Annexin V, Thrombomodulin, high- and low-molecular weight kininogens. Anti-prothrombin antibodies are detected in approximately 50% of the antiphospholipid-positive patients; conversely, limited data are available regarding the prevalence the other antibodies. ‘Cofactors' are necessary for the expression of both the immunological and the functional properties of their respective antiphospholipid antibodies. In particular, the recognition of the calcium-mediated prothrombin/lipid complex by anti-prothrombin antibodies hampers prothrombin activation, thus causing the prolongation of the phospholipid-dependent coagulation reactions. The interaction between antiphospholipid antibodies and natural inhibitors of coagulation such as activated Protein C, its non-enzymatic accessory protein Protein S or Thrombomodulin might increase the risk to develop thromboembolic events. Similarly, the presence of antibodies to surface-bound Annexin V has been hypothesized to play a role in recurrent abortions and fetal deaths. However, to clearly establish whether and which antiphospholipid antibodies represent risk factors for the thromboembolic events of the antiphospholipid syndrome, further studies of their behaviour and properties as well as the identification and characterization of (possibly) other antibodies are required.

scholarly journals Prevention of Pregnancy Complications in Antiphospholipid Syndrome

2020 ◽  
Vol 40 (02) ◽  
pp. 174-183
Author(s):  
Andreas Czwalinna ◽  
Frauke Bergmann
Keyword(s):  
Antiphospholipid Syndrome ◽  
Pregnancy Complications ◽  
Antiphospholipid Antibodies ◽  
Birth Rate ◽  
Clinical Symptoms ◽  
Adverse Pregnancy Outcome ◽  
Live Birth Rate ◽  
Obstetric Antiphospholipid Syndrome ◽  
Adverse Pregnancy ◽  
Definition Of

AbstractDespite a lot of research on antiphospholipid antibodies (aPL), standardization of test systems, and better definition of its clinical symptoms, the pathomechanism of this acquired autoimmune disease is not yet fully explained. Progress in treatment increased the live birth rate in 70 to 80% of women suffering from obstetric antiphospholipid syndrome (OAPS). However, still 20 to 30% will develop adverse pregnancy outcome. Lack of awareness of this disorder as the cause for pregnancy complications is very harmful to mothers and to their newborns. Complications can be avoided or minimized by proper treatment. The aim of this article is to increase the awareness of gynecologists and medical personal for OAPS.

Correlation between indicators of hemostasis system activity and antiphospholipid antibodies levels in women with miscarriage

GYNECOLOGY ◽  
2019 ◽  
Vol 21 (5) ◽  
pp. 53-58
Author(s):  
Elena N Kravchenko ◽  
Anastasiia A Goncharova
Keyword(s):  
Antiphospholipid Syndrome ◽  
Antiphospholipid Antibodies ◽  
Antibody Formation ◽  
Pregnancy Termination ◽  
Annexin V ◽  
Infectious Agent ◽  
Coagulation System ◽  
Hemostasis System ◽  
Reproductive Losses ◽  
Negative Effect

Aim. To study the correlation between the activity indicators of the blood coagulation system and the content of antiphospholipid antibodies in women with miscarriage, depending on the number of reproductive losses. Materials and methods. 137 cards of women with a history of pregnancy termination were analyzed, divided into 2 groups according to the principle of presence/absence of plasmapheresis in the treatment regimen at the stage of pregravid preparation, followed by ranking into 2 subgroups according to the principle of presence/absence of TORCH infection activity. Results. The highest correlation was found for the presence of autoantibodies against cardiolipin with the severity of antiphospholipid syndrome. Antibodies to b2-glyco-protein-1 were the second parameter in the level of correlation with the number of reproductive losses. The negative effect, diagnostic and pathogenetic value, first of all, of IgG is proved in comparison with IgM, IgG to cardiolipin, IgG to annexin V, IgG to cardiolipin and lupus anticoagulant. The main exogenous cause of antibody formation in AFL is an infectious agent. A key endogenous factor in antibody formation is recognized as a violation of endothelial hemostasis. Conclusion. The correlation relationships between the initial level and the dynamics of the content of antiphospholipid antibodies, the number of gestational losses, as well as a number of parameters of the hemostasis system were revealed and interpreted. An independent negative effect on the laboratory parameters of the antiphospholipid syndrome of gestational losses in an amount of more than two was revealed.

The Strong Positive Correlation between Factor VII Clotting Activity Using Bovine Thromboplastin and the Activated Factor VII Level

1995 ◽  
Vol 73 (03) ◽  
pp. 429-434 ◽  
Author(s):  
Kazuomi Kario ◽  
Takefumi Matsuo ◽  
Reiko Asada ◽  
Toshiyuki Sakata ◽  
Hisao Kato ◽  
...  
Keyword(s):  
Risk Factor ◽  
Bovine Brain ◽  
Factor Vii ◽  
Rabbit Brain ◽  
Strong Positive Correlation ◽  
Chromogenic Substrate ◽  
Moderate Correlation ◽  
Positive Correlation ◽  
Activated Factor Vii

SummaryWe compared factor VII clotting activity (FVIIc) assays using different thromboplastins to determine which is the most sensitive for activated FVII (FVIIa) or for FVII antigen (FVIIag). FVIIc levels were measured using thromboplastins derived from bovine brain (FVIIc Bov), human placenta (FVIIc Hum), and rabbit brain (FVIIc Rab). FVIIa levels were measured by fluorogenic assays using human soluble tissue factor (rsTF) or bovine rsTF. We also measured FVII activity by an amidolytic assay (FVIIc:am Hum) using human thromboplastin and a chromogenic substrate for thrombin. FVIIag levels were determined by ELISA. In the FVIIa assay, the reaction time obtained from using bovine rsTF was shorter than that with human rsTF, suggesting that the interaction of plasma FVIIa with bovine rsTF was stronger than with human rsTF. The plasma FVIIa levels measured using human rsTF and bovine rsTF were almost the same (r=0.947, p<0.0001). Among the three FVIIc assays, FVIIc Bov had the strongest positive correlation with the plasma FVIIa level (r=0.886, p<0.000l), but had no correlation with FVIIag. An increase of 1 ng/ml in the plasma FVIIa level yielded a 27.9% increase of FVIIc Bov. Plasma FVIIc Hum and FVIIc:am Hum showed moderate correlations with both FVIIa (r=0.520, p<0.02 and r=0.569, p<0.01, respectively) and FVIIag (r=0.438, p<0.05 and r=0.468, p<0.05, respectively). FVIIc Rab had the lowest correlation with FVIIa (r=0.367, p<0.1), but had a moderate correlation with FVIIag (r=0.436, p<0.05). After in vitro cold activation, FVIIc Bov levels increased the most and FVIIc:am levels showed the least change. These findings indicate that consideration of the thromboplastin used for assay is necessary when assessing the clinical significance of FVII activity as a cardiovascular risk factor.

The clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome

2020 ◽  
Author(s):  
Dong-mei Yin ◽  
Philip de Groot ◽  
Marisa Ninivaggi ◽  
Katrien M.J. Devreese ◽  
Bas de Laat
Keyword(s):  
Antiphospholipid Syndrome ◽  
Clinical Relevance ◽  
Antiphospholipid Antibodies ◽  
Odds Ratio ◽  
Lupus Anticoagulant ◽  
Solid Phase ◽  
Control Group ◽  
Domain I ◽  
Normal Controls ◽  
Better Than

Background: Patients positive for three types of antiphospholipid antibodies (aPLs) (triple positivity) have been identified at a high risk for thrombotic events. However, the clinical significance of isolated lupus anticoagulant (LAC) positivity is debated. Objectives: To investigate the clinical relevance of isolated LAC. Patients/Methods 456 patients were enrolled in this study; 66 antiphospholipid syndrome patients and 390 control patients. The control group existed of autoimmune patients (n=91), patients with thrombosis but without aPLs (n=127) and normal controls (n=172). The criteria LAC, anti-cardiolipin (anti-CL) and anti-beta2glycoprotein I (anti-β2GPI) IgG and IgM and the non-criteria IgA anti-CL and anti-β2GPI, anti-domain I (anti-DI) of β2GPI IgG and anti-phosphatidylserine/prothrombin (anti-PS/PT) IgG and IgM were detected according to the ISTH guidelines for solid phase assays. Results: 70 patients were positive for LAC, of which 44 were negative for both anti-β2GPI and anti-CL. We found that isolated LAC proved to be strongly associated with vascular thrombosis (Odds ratio (OR) (95% CI) 7.3 (3.3-16.1)), even better than triple positive samples (OR 4.3 (1.6-12.2)). The titers of the anti-PS/PT IgG and IgM were significantly higher in triple positivity samples compared to samples with isolated LAC positivity. The majority of single LAC positives were anti-PS/PT negative. We observed that LAC positivity was weaker in isolated LAC positive patients compared to LAC activity in triple positive patients. Conclusions: Isolated LAC was highly associated with thrombosis. The presence of anti-PS/PT could not explain LAC positivity in isolated LAC. Isolated LAC showed a weaker LAC activity compared to triple positive patients.

Sign in / Sign up

Export Citation Format

Share Document